Editing Antiandrogen (section)

====Early puberty====
Antiandrogens are used to treat [[precocious puberty]] in boys.<ref name="pmid18345393">{{cite journal | vauthors = Brito VN, Latronico AC, Arnhold IJ, Mendonça BB | title = Update on the etiology, diagnosis and therapeutic management of sexual precocity | journal = Arq Bras Endocrinol Metabol | volume = 52 | issue = 1 | pages = 18–31 | date = February 2008 | pmid = 18345393 | doi = 10.1590/S0004-27302008000100005 | doi-access = free }}</ref><ref name="pmid6205409">{{cite journal | vauthors = Tindall DJ, Chang CH, Lobl TJ, Cunningham GR | title = Androgen antagonists in androgen target tissues | journal = Pharmacol. Ther. | volume = 24 | issue = 3 | pages = 367–400 | date = 1984 | pmid = 6205409 | doi = 10.1016/0163-7258(84)90010-x}}</ref><ref name="pmid2462132">{{cite journal | vauthors = Namer M | title = Clinical applications of antiandrogens | journal = J. Steroid Biochem. | volume = 31 | issue = 4B | pages = 719–29 | date = October 1988 | pmid = 2462132 | doi = 10.1016/0022-4731(88)90023-4}}</ref><ref name="pmid3109366">{{cite journal | vauthors = Fraser HM, Baird DT | title = Clinical applications of LHRH analogues | journal = Baillière's Clin. Endocrinol. Metab. | volume = 1 | issue = 1 | pages = 43–70 | date = February 1987 | pmid = 3109366 | doi = 10.1016/S0950-351X(87)80052-6}}</ref> They work by opposing the effects of androgens and delaying the development of [[secondary sexual characteristic]]s and onset of changes in [[sex drive]] and [[sexual function|function]] until a more appropriate age.<ref name="pmid18345393" /><ref name="pmid6205409" /> Antiandrogens that have been used for this purpose include [[cyproterone acetate]], [[medroxyprogesterone acetate]], GnRH modulators, [[spironolactone]], [[bicalutamide]], and [[ketoconazole]].<ref name="pmid18345393" /><ref name="pmid3109366" /><ref name="pmid10969925">{{cite journal | vauthors = Laron Z, Kauli R | title = Experience with cyproterone acetate in the treatment of precocious puberty | journal = J. Pediatr. Endocrinol. Metab. | volume = 13 | issue = Suppl 1 | pages = 805–10 | date = July 2000 | pmid = 10969925 | doi = 10.1515/jpem.2000.13.s1.805| s2cid = 25398066 }}</ref><ref name="pmid1838080">{{cite journal | vauthors = Neumann F, Kalmus J | title = Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience | journal = Exp. Clin. Endocrinol. | volume = 98 | issue = 2 | pages = 71–80 | date = 1991 | pmid = 1838080 | doi = 10.1055/s-0029-1211103 }}</ref><ref name="pmid1903104">{{cite journal | vauthors = Holland FJ | title = Gonadotropin-independent precocious puberty | journal = Endocrinol. Metab. Clin. North Am. | volume = 20 | issue = 1 | pages = 191–210 | date = March 1991 | pmid = 1903104 | doi = 10.1016/s0889-8529(18)30288-3}}</ref><ref name="pmid16361981">{{cite journal | vauthors = Reiter EO, Norjavaara E | title = Testotoxicosis: current viewpoint | journal = Pediatr Endocrinol Rev | volume = 3 | issue = 2 | pages = 77–86 | date = December 2005 | pmid = 16361981 }}</ref> Spironolactone and bicalutamide require combination with an [[aromatase inhibitor]] to prevent the effects of unopposed [[estrogen]]s, while the others can be used alone.<ref name="pmid18345393" /><ref name="pmid1903104" /><ref name="pmid16361981" />